Bringing a new drug to market isn’t cheap. So now, pharmaceutical firms are contracting research out to China in a bid to cut costs. A whole new industry has already sprung up to support drug testing. Eoin Gleeson looks at what’s going on, and picks the best bet in the sector.
Articles written by Eoin Gleeson
China’s demand for milk is on the rise. But a recent contamination scandal caused panic and led to the closure of several suppliers. But for the brands that consumers still trust, there is a huge opportunity for profit. Eoin Gleeson examines China’s milk industry and picks the best bet in the sector.
The release of the latest in the line of Modern Warfare video games demonstrates just how big the market is, where a new game’s takings dwarf those of movie openings. And though it’s been a lean year for the industry, things are about to pick up. Eoin Gleeson investigates, and picks the best bet in the sector.
Beijing is to spend $125bn over the next three years on thousands of new clinics and hospitals. That will be a major boost to China’s medical device industry as money is spent on locally produced, low cost medical equipment. Eoin Gleeson examines the sector, and picks the best company to invest in now.
As fast-food culture sweeps the globe, firms in the sector are on the rise. And that’s yielding some tasty investment opportunities, say John Stepek and Eoin Gleeson.
The sea is the world’s largest untapped source of renewable energy. But harnessing it is difficult and costly. But now, with the backing of venture capitalists, governments and utilities, it may soon compete with other energy sources. Eoin Gleeson investigates, and picks the best bet in the sector.
Those technology firms that survived the dotcom bust of the late 1990s have spent much of the time since hoarding money. Now they are one of the few industries with spare cash, and there is talk of a tech-led recovery. Eoin Gleeson investigates, and picks the best bet in the sector.
Commercial property in America is in bad shape. But one property sector is profiting nicely from the US’s ageing population, says Eoin Gleeson.
Radioactive isotopes, which are used in 18 million medical procedures a year in the US alone, are in critically short supply. That means excellent opportunities for profit.
One hundred thousand elderly Californians could hold the key to the next big medical breakthrough. And better yet, you can profit from it – here’s how.